

MEDICAL TECHNOLOGY M&A PULSE

THIRD QUARTER 2021



Q3'21

INSIDE THIS ISSUE

Trends in Medical Technology	PAGE 4
Medical Technology M&A Activity	PAGES 5-9
Q3 2021 Public Market Summary	PAGES 10-13
Venture Capital Activity Overview	PAGE 14

PMCF Medical Technology Team

ABOUT PMCF

P&M Corporate Finance ("PMCF"), a U.S. registered broker/dealer, is an investment bank focused exclusively on middle market transactions with professionals in Chicago, Detroit, Denver, and across the globe through Corporate Finance International partners. Offering a depth of advisory services, PMCF helps clients worldwide meet their sale, acquisition, financing, and strategic growth objectives. Additional information on PMCF can be found by visiting our website, pmcf.com.

INVESTMENT BANKING SERVICES:

- Mergers & Acquisitions
- Carve-outs & Divestitures
- Strategic Assessments
- Transaction Readiness Planning
- Capital Raising



BRYAN HUGHES
Managing Director
312.602.3636
Bryan.Hughes@pmcf.com



MATT JAMISON
Managing Director
312.602.3583
Matt.Jamison@pmcf.com



MIKE BROOKS
Vice President
312.602-3644
Mike.Brooks@pmcf.com



JAKE STESLICKI
Associate
248.603.5369
Jake.Steslicki@pmcf.com

Medical Technology Industry Expertise

In the medical technology sector, it takes a highly focused approach to execute a transaction efficiently. And it requires the constant monitoring of new procedures, technology and product development, and overall market trends. At PMCF, our Medical Technology team brings this dedication and market knowledge to every transaction. Our transaction expertise in the medical device, bio-pharmaceutical, and healthcare sectors, combined with industry relationships and a proprietary healthcare consulting service offering, afford us a unique perspective in the industry.

Medical Devices	Contract Research	Clinical Services	Therapeutics
Healthcare	Contract Manufacturing	Behavioral Health	Managed Care
Drug Delivery	Bio-Pharmaceutical	Specialty Pharmacy	Specialty Services

SELECT RECENT PMCF MEDICAL TECHNOLOGY TRANSACTIONS



2021 Q3 Market Summary


2021 Q3: MARKETS CONTINUE TO SHINE

- Despite headwinds from an uptick in COVID-19 cases due to the surge of the delta variant, the third quarter continued 2021's trend of robust M&A activity and strong public equity performance across sectors. Investors in both the private and public markets remain bullish, with early Q4 signs indicating that strong performance will continue, ending the year on a high note.
- Total announced M&A transactions in Q3 took a slight step back from Q2's record highs, but remained strong, up 17% over Q3 of 2020, and 21% from 2020's quarterly average. With potential changes to capital gains tax rates still a possibility, business owners continue to aggressively seek to pursue sale transactions. This, paired with significant acquisition interest from both private equity investors as well as strategic acquirers has led to both the active transaction market as well as attractive valuations for sellers across sectors.
- During the year to date, PMCF's four Medical Technology indices have all seen solid growth, though they were buffeted by a market wide sell-off at the end of the third quarter. Cardiovascular Medical Devices was the strongest performing sector through three quarters, up 12.8% on the year, just above the Dow Jones Industrial Average, which closed up 12.0% and behind the benchmark S&P 500 Growth Index which finished up 17.6%.

KEY 2021 EVENTS TIMELINE

- January 4, 2021 | United Kingdom Begins Administering AstraZeneca Vaccine
- February 1, 2021 | More Americans Vaccinated Than Infected with COVID-19
- March 19, 2021 | U.S. Administers its 100 Millionth COVID-19 Vaccine Shot
- April 2, 2021 | CDC Announces Vaccinated Travelers Can Travel Domestically at Low Risk
- April 16, 2021 | U.S. Administers its 200 Millionth COVID-19 Vaccine Shot
- April 17, 2021 | Global Death Count From COVID-19 Reaches 3 Million People
- May 25, 2021 | Half of U.S. Adults Are Fully Vaccinated Against COVID-19
- June 15, 2021 | U.S. Passes 600,000 Deaths from COVID-19
- July 7, 2021 | Delta Variant Surpassed Alpha Variant to Become Dominant U.S. Strain
- August 23, 2021 | U.S. FDA Grants Full Approval to the Pfizer/BioNTech COVID-19 Vaccine
- October 1, 2021 | U.S. Passes 700,000 Deaths from COVID-19


PMCF MEDICAL TECHNOLOGY INDICES PERFORMANCE



Sources: Capital IQ, PitchBook, Company Reports, Fraser


Trends in Medical Technology

U.S. PERSONAL HEALTH CARE SERVICES EXPENDITURES (\$B)




- Personal Health Care Service expenditures serve as a proxy for activity in the broader Healthcare and Medical industries, with high levels of service expenditures correlated with strong performance in other sectors.
- After a brief downturn due to broad health care system disruptions and temporary delays of elective procedures, personal health care service expenditures have slightly exceeded pre-pandemic levels and continue to grow steadily, up 1.8% between the second and third quarter of 2021.

U.S. MEDICAL INSTRUMENT & SUPPLY MANUFACTURING (\$B)



- The Medical Device, Instrument, Technology, and Supply industries in the United States together constitute one of the most critical and advanced industries in the world, leveraging advances in biotechnology, materials science, robotics, and therapeutics.
- Growth between 2020 and 2021 has been strong in the year-to-date period. The industry continues to face supply chain related disruptions, but the short-term outlook is much brighter than a year ago, and long-term growth prospects remain strong.

MEDICAL EQUIPMENT & SUPPLY PRODUCER PRICE INDEX (PPI)



- As medical industry revenues are growing, producer costs are also rising, often due to COVID-19 safety measures and supply chain disruptions. The Bureau of Labor Statistics provides a Producer Price Index (PPI) that measures the average change in selling price of domestic output. The Medical Equipment & Supply PPI value serves as a broad proxy for Medical industry costs.
- The PPI is based on a 2003 baseline equal to 100. Currently the index is at 123.2, up from 121.2 in Q3 2020.

Sources: PMCF Research, FRED, US Census Bureau, IBIS

Medical Technology M&A Activity

Medical Equipment

Baxter International (NYSE: BAX) acquires Hill-Rom Holdings (NYSE:NRC)

September 2021 – Baxter International (NYSE:BAX), a leading global medical products company, announced it entered into a definitive agreement to acquire Hillrom (NYSE:HRC), a medical technology leader. Upon completion of the transaction Baxter will pay \$156 in cash for each outstanding share of Hillrom common stock, resulting in a purchase price of \$10.5 billion, at an implied total enterprise value of \$12 billion, representing a 19.9x TEV / LTM EBITDA multiple. The deal is expected to close in 2022. “Baxter and Hillrom share a common vision for transforming healthcare to better serve all patients and providers,” said José (Joe) E. Almeida, Baxter’s chairman, president and chief executive officer. “Patients increasingly want to receive their care at home or nearby, while hospitals and other care providers are increasingly using digital health technologies to expand access, improve quality and lower costs.” John Groetelaars, Hillrom’s president and chief executive officer, said, “We are proud of the steps we have taken to transform Hillrom into a medical technology leader with an innovative portfolio of connected care solutions. Today’s milestone announcement represents a win-win for all stakeholders.”

Therapeutic Device

Boston Scientific (NYSE:BSX) acquires Devoro Medical

September 2021 – Boston Scientific Corporation (NYSE: BSX) announced an agreement to acquire Devoro Medical, Inc., developer of the WOLF Thrombectomy® Platform. The WOLF technology is an innovative system that targets and captures blood clots using prongs that retrieve and remove thrombi in the arterial and venous systems. In 2019 Boston Scientific invested in Devoro and acquired ~16% equity. This transaction, worth up to \$269M, is for the remaining 84% of Devoro. “The addition of the WOLF platform advances our efforts to ensure physicians have the right tools to improve procedural efficiencies,” said Jeff Mirviss, executive vice president and president, Peripheral Interventions, Boston Scientific. “Clot management remains a core focus of our business, and upon commercialization, this highly differentiated technology will complement and expand our offerings to a full suite of interventional strategies for thromboemboli.” The transaction is expected to close in the fourth quarter of 2021, subject to customary closing conditions.

Consumable & Disposable

Silgan Holdings (Nasdaq:SLGN) acquires Unicep Packaging


September 2021 – Silgan Holdings Inc. (Nasdaq:SLGN), a leading supplier of sustainable rigid packaging solutions for consumer goods products, acquired Unicep Packaging. Unicep is a specialty contract manufacturer, developing, formulating, manufacturing, and selling precision dosing dispensing packaging solutions, such as diagnostic test components, oral care applications and skin care products, primarily for the health care, diagnostics, animal health, oral care and personal care markets. The transaction was valued at \$237 million, implying a ~13x multiple on 2021 adjusted EBITDA. “Unicep is a clear leader in the rapid development and manufacturing of differentiated precision dosing dispensing packaging solutions for applications in health care, diagnostics and personal care. This acquisition further expands and extends our precision dosing capabilities and comprehensive product offering into new and existing markets,” said Adam Greenlee, President and CEO. “The Unicep team has combined a high-touch commercial philosophy with a proprietary operating platform to excel at meeting the unique requirements of their customers. The business broadens our exposure to health care and Point-of-Care diagnostics markets, has existing capacity for continued growth, complements our global Dispensing and Specialty Closures franchise and is scalable across our global footprint.”

M&A Activity Roundup


TRENDS IN MEDICAL TECHNOLOGY M&A

- M&A transaction volume in the third quarter of 2021 was up significantly from the same period in 2020, with 170 transactions announced in 2021, compared to 145 announced in 2020's third quarter (143 recorded in Q2 of 2019). Since the inception of the PMCF medical technology database in 2012, 2021 has seen the strongest transaction volume and has already exceeded even the annual transactions of many prior years.
- Average transaction value during the quarter was lower than the same period in 2020. Of the 170 total announced transactions, 70 disclosed enterprise value, averaging \$577 million, down from \$851 million in Q2 2020. The largest announced deal this quarter was GE Healthcare's purchase of BK Medical.
- M&A transactions involving Therapeutic Device, Equipment, and Service target companies were again the three most active segments, making up 69% of announced deals, slightly higher than in Q2.

TRANSACTIONS BY PRODUCT SEGMENT - Q3 2021



MEDICAL DEVICE M&A TRANSACTION METRICS



Period	Mean/Median	Transaction Value (\$MM)	TEV/REV	TEV/EBITDA
2021 Q3	Mean	\$577.0	7.64x	18.62x
2021 Q3	Median	\$40.6	4.10x	14.75x
2020 Q3	Mean	\$850.8	10.37x	50.97x
2020 Q3	Median	\$25.8	2.78x	11.11x
2020	Mean	\$416.7	5.28x	30.54x
2020	Median	\$24.3	2.40x	13.57x
2019	Mean	\$762.3	6.76x	18.06x
2019	Median	\$24.8	2.83x	14.08x
2018	Mean	\$633.8	6.64x	17.52x
2018	Median	\$57.5	2.50x	13.63x


Sources: Capital IQ, PitchBook, Company Reports, PMCF

Medical Equipment M&A


TRENDS IN MEDICAL EQUIPMENT M&A

- Medical Equipment M&A activity increased significantly from the same period in 2020, with total announced transactions climbing from 32 to 44. This was slightly lower than Q2 activity (47), though still near the record high volume marks set during the first 2 quarters of 2021.
- Announced transactions among public acquirers, private acquirers, and PE to PE were all up, with public acquirers leading the way at 45% of transactions. Private equity volume fell slightly compared to volume in the same quarter last year.
- In cross border transactions, domestic transactions saw a strong increase from a year ago, with 28 transactions involving U.S. based buyers and sellers. International deals remained active, with 14 transactions involving international targets during the quarter.
- Furniture/Equipment was the leading end market within the broader Medical Equipment category, followed by Home Health, Monitoring, and Other. In the first 9 months of 2021, nearly every category has surpassed or is on pace to exceed its 2019 and 2020 volume levels.

FINANCIAL VS. STRATEGIC BUYER MEDICAL EQUIPMENT



MEDICAL EQUIPMENT TRANSACTIONS BY BUYER TYPE



TRANSACTIONS BY END MARKET

End Market	2018	2019	2020	20 Q3	21 Q3
Acute Care	1	1	4	-	-
Aesthetic	3	2	-	-	-
Cardiovascular	3	5	3	1	2
Drug Delivery	9	1	5	1	-
Furniture/Equipment	39	37	25	5	14
Home Health	5	10	9	2	4
Hospital Care	3	7	21	8	3
Infection Control	6	5	1	-	-
IVD	5	-	1	-	2
Monitor	12	8	12	2	4
Neurovascular	-	2	2	1	2
Ophthalmology	4	7	6	2	1
Ortho	2	1	-	-	-
Other	17	19	11	2	4
Respiratory	7	7	6	1	3
Support	5	9	6	1	2
Surgical	27	15	17	6	3
Total	148	136	129	32	44

CROSS BORDER TRANSACTION TRENDS

Seller-to-Buyer	2018	2019	2020	20 Q3	21 Q3
Int'l-to-Int'l	65	66	57	13	11
U.S.-to-Int'l	15	11	12	3	3
U.S.-to-U.S.	59	48	46	11	28
Int'l-to-U.S.	9	11	14	5	2
Total	148	136	129	32	44


Sources: Capital IQ, PitchBook, Company Reports, PMCF

Therapeutic Device M&A


TRENDS IN THERAPEUTIC DEVICE M&A

- Therapeutic Device M&A activity was down quarter over quarter, with transaction volume dropping from 43 in Q2 to 30 in Q3 2021. Third quarter activity saw similar levels as the same quarter in 2020, with the majority (25 of the 30) of activity in the sector again coming from strategic buyers.
- Public buyers historically have been the most active segment in the Therapeutic Device space, including in Q3 where 20 of the 30 announced transactions involved a public acquirer.
- Transactions in the Orthopedic and Cardiovascular end markets were again near the most active, behind only the diversified Other end market. Respiratory and Ophthalmology were also active segments with their YTD transactions through three quarters exceeding their 2020 totals already.
- The international M&A market had announced transactions nearly exceeding U.S. based activity during the quarter, with 53% of announced transactions involving at least one international party. Cross-border M&A activity continues to persist despite facing headwinds from the COVID-19 pandemic and global supply chain issues.

FINANCIAL VS. STRATEGIC BUYER THERAPEUTIC DEVICE



THERAPEUTIC DEVICE TRANSACTIONS BY BUYER TYPE



TRANSACTIONS BY END MARKET

End Market	2018	2019	2020	20 Q3	21 Q3
Acute Care	-	6	3	-	1
Aesthetic	-	-	-	-	-
Cardiovascular	9	7	10	6	4
Drug Delivery	2	-	2	1	-
Furniture/Equipment	-	1	3	2	-
Home Health	9	2	5	1	-
Hospital Care	2	-	-	-	1
Infection Control	-	3	-	-	-
IVD	1	3	1	-	-
Monitor	1	-	2	1	-
Neurovascular	-	5	1	-	-
Ophthalmology	12	13	7	3	3
Ortho	27	33	37	10	4
Other	32	23	36	9	12
Respiratory	2	3	3	-	3
Support	1	1	2	1	2
Surgical	4	2	5	-	-
Total	102	102	117	34	30

CROSS BORDER TRANSACTION TRENDS

Seller-to-Buyer	2018	2019	2020	20 Q3	21 Q3
Int'l-to-Int'l	49	34	47	18	12
U.S.-to-Int'l	7	6	10	1	4
U.S.-to-U.S.	35	51	46	11	14
Int'l-to-U.S.	11	11	14	4	-
Total	102	102	117	34	30


Sources: Capital IQ, PitchBook, Company Reports, PMCF

Consumable & Disposable M&A


TRENDS IN CONSUMABLE & DISPOSABLE M&A

- The third quarter in 2021 exhibited similar Consumable & Disposable M&A activity as did Q3 of 2020. Activity held strong from the previous quarter, with 18 total announced transactions in each quarter. Strategic buyers drove much of this activity, accounting for 12 out of the 18. Financial buyers slowed their 2021 pace, with involvement in 3 announced transactions.
- Public acquirers bounced back from a slow 2021 Q2, increasing activity from 5 to 12 announced transactions. Private equity groups and private acquirer transaction volumes slowed slightly, each recording 3 announced deals.
- Looking at cross border trends in the sector, Consumable and Disposable M&A continues to experience significant international involvement, with 2/3 of all transactions involving an international party.
- Unsurprisingly, Infection Control persists as the leading end market within the Consumable & Disposable sector, with 5 transactions announced. This is slightly less than the quarter prior, but YTD volume has already surpassed the annual 2020 level.

FINANCIAL VS. STRATEGIC BUYER CONSUMABLE & DISP.



CONSUMABLE & DISP. TRANSACTIONS BY BUYER TYPE



TRANSACTIONS BY END MARKET

End Market	2018	2019	2020	20 Q3	21 Q3
Acute Care	7	8	8	2	2
Aesthetic	1	2	-	-	-
Cardiovascular	3	2	-	-	-
Drug Delivery	3	5	8	4	2
Furniture/Equipment	-	1	-	-	-
Home Health	4	4	2	1	-
Hospital Care	2	9	6	3	3
Infection Control	11	2	18	6	5
IVD	10	5	1	-	1
Monitor	-	-	-	-	-
Neurovascular	-	-	-	-	-
Ophthalmology	-	3	1	-	-
Ortho	-	-	1	1	-
Other	16	22	11	1	3
Respiratory	1	2	2	-	-
Support	3	6	3	-	2
Surgical	15	10	-	-	-
Total	76	81	61	18	18

CROSS BORDER TRANSACTION TRENDS

Seller-to-Buyer	2018	2019	2020	20 Q3	21 Q3
Int'l-to-Int'l	30	42	35	9	10
U.S.-to-Int'l	6	9	4	1	2
U.S.-to-U.S.	31	25	21	8	6
Int'l-to-U.S.	9	5	1	-	-
Total	76	81	61	18	18

Sources: Capital IQ, PitchBook, Company Reports, PMCF

Diversified Medical Device Public Comparables

PUBLIC DIVERSIFIED MEDICAL DEVICE COMPANY COMMENTARY


- “The third quarter was impacted by COVID more than we anticipated as the Delta variant surged globally and some elective procedures were deferred.” – Michael Mahoney, Boston Scientific Corporation Chairman, President and CEO
- “I think we’ve also learned a lot about understanding kind of the difference between symptomatic testing and screening testing. And we started to pay much closer attention to understanding the channels and the platforms that are more aligned to symptomatic testing versus screening testing. And we can definitely see a correlation on the symptomatic testing with cases going up, cases going down. What we don’t see that correlation is on screening.” – Robert Ford, Abbott Laboratories President, CEO, & Director

DIVERSIFIED MEDICAL DEVICE PUBLIC COMPARABLES SUMMARY


Company Name	LTM as of	Cash (\$MM)	Debt (\$MM)	Market Cap (\$MM)	TEV (\$MM)	TEV/REV	TEV/EBITDA	P/E
Abbott Laboratories	9/30/2021	8,944	18,501	207,792	217,578	5.4x	18.2x	33.0x
Baxter International Inc.	9/30/2021	3,258	6,440	40,638	43,865	3.6x	15.1x	37.3x
Becton, Dickinson and Company	6/30/2021	3,177	17,733	70,270	84,828	4.3x	14.4x	38.6x
Boston Scientific Corporation	9/30/2021	2,675	9,468	62,365	69,158	6.2x	23.0x	118.6x
Intuitive Surgical, Inc.	9/30/2021	4,132	0	120,121	116,038	22.4x	60.1x	75.4x
Johnson & Johnson	7/4/2021	25,306	33,483	422,434	430,611	4.8x	13.9x	24.1x
Medtronic plc	7/30/2021	10,595	25,964	171,335	186,882	5.9x	19.9x	44.5x
Smith & Nephew plc	7/3/2021	1,387	3,566	15,244	17,423	3.5x	14.4x	28.1x
Stryker Corporation	9/30/2021	2,639	13,057	101,145	111,563	6.9x	23.6x	49.2x
High		25,306	33,483	422,434	430,611	22.4x	60.1x	118.6x
Mean		6,901	14,246	134,594	141,994	7.0x	22.5x	49.9x
Median		3,258	13,057	101,145	111,563	5.4x	18.2x	38.6x
Low		1,387	0	15,244	17,423	3.5x	13.9x	24.1x

As of October 01, 2021

DIVERSIFIED MEDICAL DEVICE MULTIPLES



DIVERSIFIED MEDICAL DEVICE INDEX



EV/EBITDA multiples for the Diversified Medical Device (“DMD”) sector finished the third quarter of 2021 slightly below the same period in 2020, 22.3x vs 24.9x respectively. Multiples have come down slightly from the 2nd quarter of 2021, where average EV/EBITDA was 26.2x. This modest quarter over quarter decline was led by Intuitive Surgical, which saw its EBITDA multiple drop from 71.0x to 60.1x. Average Revenue multiples exhibited slight growth, up 3% over the same period. Intuitive continues to lead the sector in revenue multiples, while the next closest is Stryker at 6.9x.

The PMCF DMD index is up 7.5% through Q3 of 2021, slightly above the mark reached at the end of Q2. After climbing steadily in August and the first part of September, the index pulled back from its high of +15.1% during the second half of the month.

Sources: Capital IQ, PitchBook, Company Reports, PMCF

Orthopedic Public Comparables

PUBLIC ORTHOPEDIC MEDICAL DEVICE COMPANY COMMENTARY


- “The impact on elective procedures was more pronounced in the United States than on other geographies outside the United States. Within the United States, there were areas of disruption in most states, but disruption was more widespread in the Southeast and Southwest portions of the country, impacting major markets like Florida and Texas throughout the quarter.” – Preston Wells, Stryker Corporation Vice President of Investor Relations
- “We continue to see the same trends in the U.S. with a good and strong recovery in China with the volumes being up to pre-COVID levels and then with a slow recovery across the big European markets, the challenge looking forward is... limited visibility to potential further outbreaks.” – Roland Diggelmann, Smith & Nephew CEO and Director

ORTHOPEDIC MEDICAL DEVICE PUBLIC COMPARABLES SUMMARY


Company Name	LTM as of	Cash (\$MM)	Debt (\$MM)	Market Cap (\$MM)	TEV (\$MM)	TEV/REV	TEV/EBITDA	P/E
Alphatec Holdings, Inc.	9/30/2021	224	356	1,260	1,416	6.8x	NM	NM
Colfax Corporation	10/1/2021	177	1,789	6,703	8,359	2.4x	14.0x	59.6x
Globus Medical, Inc.	9/30/2021	553	5	7,970	7,423	7.6x	23.6x	43.9x
NuVasive, Inc.	9/30/2021	235	1,008	3,238	4,012	3.5x	16.2x	NM
Orthofix Medical Inc.	9/30/2021	83	26	774	718	1.6x	15.0x	NM
Smith & Nephew plc	7/3/2021	1,387	3,566	15,244	17,423	3.5x	14.4x	28.1x
Stryker Corporation	9/30/2021	2,639	13,057	101,145	111,563	6.9x	23.6x	49.2x
Surgalign Holdings, Inc.	9/30/2021	68	1	152	85	0.8x	NM	NM
Zimmer Biomet Holdings, Inc.	9/30/2021	929	7,516	31,215	37,808	4.8x	15.3x	34.1x
High		2,639	13,057	101,145	111,563	7.6x	23.6x	59.6x
Mean		699	3,036	18,634	20,979	4.2x	17.4x	43.0x
Median		235	1,008	6,703	7,423	3.5x	15.3x	43.9x
Low		68	1	152	85	0.8x	14.0x	28.1x

As of October 01, 2021

ORTHOPEDIC MEDICAL DEVICE MULTIPLES



ORTHOPEDIC MEDICAL DEVICE INDEX



Revenue multiples in the Orthopedic Medical Device space has seen significant growth since 2020, sitting 15% higher than at the close of the same quarter in 2020. 2021 Q3 EBITDA multiples are slightly down from 2020 (17.1x vs. 19.6x). Both sets of multiples have seen a pullback from Q2 of 2021, a period in which EBITDA multiples dropped from 23.9x to 17.1x, a 40% decline. Globus had the highest EBITDA multiple during the quarter, trading at 23.6x, while also holding the highest revenue multiple at 7.6x, both slightly lower than the previous quarter.

PMCF's OMD index was up 4.4% through the end of Q3, lagging the S&P 500 Growth Index YTD performance which was up 17.6%. The OMD index has continued to oscillate around the +5% level since its strong gains in April.

Cardiovascular Public Comparables

PUBLIC CARDIOVASCULAR MEDICAL DEVICE COMPANY COMMENTARY


- “Everyone is trying to navigate the seemingly ever-changing dynamics surrounded COVID and the impacts are certainly being felt in all areas of our business, our customers, hospitals, clinicians, patients and as Raul will detail to you later in the call, in our supply chain and logistics as well.” – Fred Lampropoulos, Merit Medical Systems Chairman, CEO, & President
- “75% of our U.S. sites grew. So we have a playbook to adapt to Delta. What was new is a little bit of the shortages of staffing. So the procedures want to be done. The physicians are engaged, but they don’t have the surgical techs or the cath lab techs or ICU capacity that limits use. So that impacted about 25%. If we look at our -- just the same metric for cardiogenic shock, 83% of our regions grew.” – Michael Minogue, Abiomed, Chairman, CEO & President

CARDIOVASCULAR MEDICAL DEVICE PUBLIC COMPARABLES SUMMARY


Company Name	LTM as of	Cash (\$MM)	Debt (\$MM)	Market Cap (\$MM)	TEV (\$MM)	TEV/REV	TEV/EBITDA	P/E
Abiomed, Inc.	9/30/2021	651	8	14,673	14,030	14.8x	47.3x	95.6x
AngioDynamics, Inc.	8/31/2021	35	34	1,017	1,015	3.4x	75.9x	NM
Cardiovascular Systems, Inc.	6/30/2021	207	23	1,372	1,187	4.6x	NM	NM
CryoLife, Inc.	6/30/2021	50	365	898	1,213	4.3x	26.0x	NM
Edwards Lifesciences Corporation	9/30/2021	1,795	684	69,987	68,877	14.0x	40.4x	48.7x
LeMaitre Vascular, Inc.	9/30/2021	67	16	1,171	1,120	7.9x	23.1x	38.7x
Medtronic plc	7/30/2021	10,595	25,964	171,335	186,882	5.9x	19.9x	44.5x
Merit Medical Systems, Inc.	9/30/2021	69	353	4,081	4,365	4.3x	24.5x	145.1x
Terumo Corporation	6/30/2021	1,693	2,254	35,487	36,048	6.1x	23.6x	43.3x
High		10,595	25,964	171,335	186,882	14.8x	75.9x	145.1x
Mean		1,685	3,300	33,336	34,971	7.3x	35.1x	69.3x
Median		207	353	4,081	4,365	5.9x	25.2x	46.6x
Low		35	8	898	1,015	3.4x	19.9x	38.7x

As of October 01, 2021

CARDIOVASCULAR MEDICAL DEVICE MULTIPLES



CARDIOVASCULAR MEDICAL DEVICE INDEX



Cardiovascular Medical Devices multiples finished 2021 Q3 marginally higher than they were a year ago, with 15% growth in EV/EBITDA and 13% growth in EV/Revenue multiples. EV/EBITDA multiples were down slightly since the end of Q2 and sit in line with the recent historical averages.

The CMD index is up 12.8% on the year, rising 5% since the end of Q2. Given the strong performance, the index saw a slight retreat from highs (20%) achieved at the beginning of September. The CMD index was the strongest performing of PMCF’s four tracked medical indices. Despite strong relative performance within the healthcare sector, the CMD index still lags the broader S&P 500 Growth Index.

Sources: Capital IQ, PitchBook, Company Reports, PMCF

Diversified Diagnostic Public Comparables

PUBLIC DIVERSIFIED DIAGNOSTIC COMPANY COMMENTARY


- “Testing began to increase meaningfully in mid-July and peaked in early mid-September. Our observed positivity rate peaked in mid-August and has steadily been declining across much of the country in recent weeks.” – Stephen Rusckowski, Quest Diagnostics, Chairman, President, & CEO
- “We collaborated with AstraZeneca on both a COVID prevention and treatment trial of its new long-acting antibody combination. In the trial, the investigational antibody combination demonstrated statistically significant benefit in preventing symptomatic COVID and in reducing severe COVID or death in outpatients with mild to moderate COVID, promising milestones in the development of new treatments.” – Adam Schechter, LabCorp, President, CEO & Chairman

DIVERSIFIED DIAGNOSTIC PUBLIC COMPARABLES SUMMARY


Company Name	LTM as of	Cash (\$MM)	Debt (\$MM)	Market Cap (\$MM)	TEV (\$MM)	TEV/REV	TEV/EBITDA	P/E
Abbott Laboratories	9/30/2021	8,944	18,501	207,792	217,578	5.4x	18.2x	33.0x
Becton, Dickinson and Co.	6/30/2021	3,177	17,733	70,270	84,828	4.3x	14.4x	38.6x
Danaher Corporation	10/1/2021	2,552	24,626	215,826	241,178	8.7x	25.1x	40.9x
Hologic, Inc.	6/26/2021	828	3,162	18,307	20,642	3.6x	6.7x	9.3x
Laboratory Corporation of America	9/30/2021	2,037	6,336	27,026	31,345	1.9x	6.1x	9.6x
Novartis AG	9/30/2021	8,110	34,329	182,782	209,167	4.2x	10.6x	20.8x
Quest Diagnostics Incorporated	9/30/2021	987	4,650	17,509	21,291	2.0x	6.0x	8.6x
Roche Holding AG	6/30/2021	8,671	17,561	323,707	336,511	5.0x	13.2x	21.3x
Thermo Fisher Scientific Inc.	7/3/2021	7,023	18,791	225,319	237,087	6.2x	17.5x	26.5x
High		8,944	34,329	323,707	336,511	8.7x	25.1x	40.9x
Mean		4,703	16,188	143,171	155,514	4.6x	13.1x	23.2x
Median		3,177	17,733	182,782	209,167	4.3x	13.2x	21.3x
Low		828	3,162	17,509	20,642	1.9x	6.0x	8.6x

As of October 01, 2021

DIVERSIFIED DIAGNOSTIC MULTIPLES



DIVERSIFIED DIAGNOSTIC INDEX



EV/EBITDA multiples within the Diversified Diagnostic (“DD”) industry were once behind those of PMCF’s other tracked medical sectors, closing the second quarter at 13.1x, slightly lower than the quarter prior (13.6x). The companies that led the group in terms of valuation multiples were Danaher Corp., Abbott Laboratories, and Thermo Fisher Scientific, filling the top 3 positions in each EV/EBITDA and EV/Revenue.

The DD Index performance gained significant momentum starting in June and continuing until the beginning of September, before a moderate decline during the balance of the month. For the year, the index is up 9.1%, 3% higher than it closed the second quarter.

Sources: Capital IQ, PitchBook, Company Reports, PMCF

2021 Q3 Venture Capital Activity Overview


Market activity through the third quarter of 2021 has left little doubt as to the growing importance of venture capital in public markets. Over two-thirds of year-to-date initial public offerings in the U.S. came from venture backed companies, returning over \$500 billion in exit value. Accordingly, capital continues to flow into the VC world, with average fund size increasing to almost \$200 million, well above the previous record high of \$166 million in 2020. With significant amounts of capital coming in, VCs have been highly active in deploying their funds. Just under \$240 billion of capital has been deployed through the third quarter of the year, already well above the \$166 billion deployed in 2020, which was the previous high. Deal count is also on pace to set a new high-water mark, with 11,291 deals completed through three quarters, about 1,200 off 2019's full year total. The split between the three primary deal stages is roughly even in terms of deal count, with Angel & Seed making up 38.7%, Early VC 30.4%, and Late VC 31.0%.

Median deal valuations have continued to climb across all deal stages, with each subsequent stage seeing a large % and absolute value increase in valuation year-over-year. Angel valuations are up 22.5% over 2020 levels to \$6.1M, Seed are up 28.6% to \$9M, Early VC are up 50% to \$45M, and Late VC median valuations are up a whopping 71.1% to \$120M, fueled in part by a number of mega rounds this year.


Focusing in on healthcare, HC Services & Systems are on pace to greatly exceed 2020's deal volume, setting a new record for the 16th consecutive year. Through three quarters the sector is at 986 deals, compared to 1,017 in 2020. Pharma & Biotech are also on pace to set another annual volume record at just over 1,160 deals. HC Devices & Supplies should also see 12%+ growth over 2020 based on year-to-date performance.

Comparing the three healthcare related VC industries, HC Devices & Supplies, HC Services & Systems, and Pharma & Biotech, HC Services & Supplies has been the most active sector through three quarters, with Pharma & Biotech just behind, and HC Devices & Supplies trailing further back, similar to the dynamic in 2019 and 2020.


VC INVESTMENTS IN MEDICAL SECTORS



MEDIAN PRE-MONEY VALUATION BY ROUND



DEAL COUNT BY ROUND



Angel/Seed: The company has a concept or product under development, but is likely not fully operational. Typically in existence less than 18 months.

Early: The company has a product or service in testing or pilot production. In some cases, the product may be commercially available. May or may not be generating revenues. Typically in business less than three years.

Later: Product or service is widely available. Company is generating ongoing revenue; potentially positive cash flow. More likely to be, but not necessarily, profitable.

Sources: Capital IQ, PitchBook, NVCA, PMCF

PMCF's Unique Approach to M&A Advisory

PMCF's M&A advisory and investment banking services are designed to provide company shareholders with a trusted advisor to oversee all transaction related aspects of a company sale or strategic acquisition. Our service levels, industry expertise in medical technology, and approach to managing transactions positions us favorably against a traditional investment banker. See below for some examples of our differentiation:

- Differentiated approach via senior banker leadership and direct involvement through every step of the transaction providing a consistent and highly experienced point of contact
- One of the largest, most active investment banking boutiques with a focus on specialty niche businesses
- Proven positioning and marketing processes to obtain premium valuations in company sales
- Tailored sale process provides for extensive upfront preparation, detailed company review and identification of any potential issues in advance, and buyer evaluation/diligence ensuring the right fit
- Unique sale planning approach that helps shareholders best prepare for a future sale whether its six months or several years
- Long-term and client first approach allows PMCF to provide unbiased advice



Two-time winner, Boutique Investment Banking Firm of the Year
by M&A Advisor


Awarded, Cross Border Corporate and Strategic Acquisition of the Year
by M&A Advisor

Awarded, Cross Border M&A Deal of the Year
by M&A Advisor

Awarded, Deal of the Year
by ACG Detroit

Contact Info

PMCF | INVESTMENT
BANKING



DETROIT

2 Towne Square
Suite 425
Southfield, MI 48076
Phone: 248.223.3300



CHICAGO

120 S. Riverside Plaza
Suite 2100
Chicago, Illinois 60606
Phone: 312.602.3600



DENVER

8181 E. Tufts Avenue
Suite 600
Denver, CO 80237
Phone: 720.370.8181

2 Towne Square
Suite 425
Southfield, MI 48076

Experienced Professionals. Trusted Advisors. Proven Results.

This market overview is not an offer to sell or a solicitation of an offer to buy any security. It is not intended to be directed to investors as a basis for making an investment decision. This market overview does not rate or recommend securities of individual companies, nor does it contain sufficient information upon which to make an investment decision.

P&M Corporate Finance, LLC will seek to provide investment banking and/or other services to one or more of the companies mentioned in this market overview.

P&M Corporate Finance, LLC, and/or the analysts who prepared this market update, may own securities of one or more of the companies mentioned in this market overview.

The information provided in this market overview was obtained from sources believed to be reliable, but its accuracy cannot be guaranteed. It is not to be construed as legal, accounting, financial, or investment advice. Information, opinions, and estimates reflect P&M Corporate Finance,

LLC's judgment as of the date of publication and are subject to change without notice. P&M Corporate Finance, LLC undertakes no obligation to notify any recipient of this market overview of any such change.

The charts and graphs used in this market overview have been compiled by P&M Corporate Finance, LLC solely for illustrative purposes. All charts are as of the date of issuance of this market overview, unless otherwise noted.

The PMCF Medical Technology Indices may not be inclusive of all companies in the medical technology industry and is not a composite index of the medical technology industry sector returns. Index and sector returns are past performance which is not an indicator of future results.

This market overview is not directed to, or intended for distribution to, any person in any jurisdiction where such distribution would be contrary to law or regulation, or which would subject P&M Corporate Finance, LLC to licensing or registration requirements in such jurisdiction.

For more information, check out our new website, where you can access the electronic version of this report, sign up for future emails, read our latest industry reports, and more!

